Cargando…
The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan
BACKGROUND: One of the main goals of the post-2015 global tuberculosis (TB) strategy is that no families affected by TB face catastrophic costs. We revised an existing TB patient cost measurement tool to specifically also measure multi-drug resistant (MDR) TB patients’ costs and applied it in Ethiop...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011357/ https://www.ncbi.nlm.nih.gov/pubmed/27595779 http://dx.doi.org/10.1186/s12879-016-1802-x |
_version_ | 1782451816272756736 |
---|---|
author | van den Hof, Susan Collins, David Hafidz, Firdaus Beyene, Demissew Tursynbayeva, Aigul Tiemersma, Edine |
author_facet | van den Hof, Susan Collins, David Hafidz, Firdaus Beyene, Demissew Tursynbayeva, Aigul Tiemersma, Edine |
author_sort | van den Hof, Susan |
collection | PubMed |
description | BACKGROUND: One of the main goals of the post-2015 global tuberculosis (TB) strategy is that no families affected by TB face catastrophic costs. We revised an existing TB patient cost measurement tool to specifically also measure multi-drug resistant (MDR) TB patients’ costs and applied it in Ethiopia, Indonesia and Kazakhstan. METHODS: Through structured interviews with TB and MDR-TB patients in different stages of treatment, we collected data on the direct (out of pocket) and indirect (loss of income) costs of patients and their families related to the diagnosis and treatment of TB and MDR-TB. Direct costs included costs for hospitalization, follow-up tests, transport costs for health care visits, and food supplements. Calculation of indirect costs was based on time needed for diagnosis and treatment. Costs were extrapolated over the patient’s total treatment phase. RESULTS: In total 406 MDR-TB patients and 197 other TB patients were included in the survey: 169 MDR-TB patients and 25 other TB patients in Ethiopia; 143 MDR-TB patients and 118 TB patients in Indonesia; and 94 MDR-TB patients and 54 other TB patients in Kazakhstan. Total costs for diagnosis and current treatment episode for TB patients were estimated to be USD 260 in Ethiopia, USD 169 in Indonesia, and USD 929 in Kazakhstan, compared to USD 1838, USD 2342, and USD 3125 for MDR-TB patients, respectively. These costs represented 0.82–4.6 months of pre-treatment household income for TB patients and 9.3–24.9 months for MDR-TB patients. Importantly, 38–92 % reported income loss and 26–76 % of TB patients lost their jobs due to (MDR) TB illness, further aggravating the financial burden. CONCLUSIONS: The financial burden of MDR-TB is alarming, although all TB patients experienced substantial socioeconomic impact of the disease. If the patient is the breadwinner of the family, the combination of lost income and extra costs is generally catastrophic. Therefore, it should be a priority of the government to relieve the financial burden based on the cost mitigation options identified. |
format | Online Article Text |
id | pubmed-5011357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50113572016-09-15 The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan van den Hof, Susan Collins, David Hafidz, Firdaus Beyene, Demissew Tursynbayeva, Aigul Tiemersma, Edine BMC Infect Dis Research Article BACKGROUND: One of the main goals of the post-2015 global tuberculosis (TB) strategy is that no families affected by TB face catastrophic costs. We revised an existing TB patient cost measurement tool to specifically also measure multi-drug resistant (MDR) TB patients’ costs and applied it in Ethiopia, Indonesia and Kazakhstan. METHODS: Through structured interviews with TB and MDR-TB patients in different stages of treatment, we collected data on the direct (out of pocket) and indirect (loss of income) costs of patients and their families related to the diagnosis and treatment of TB and MDR-TB. Direct costs included costs for hospitalization, follow-up tests, transport costs for health care visits, and food supplements. Calculation of indirect costs was based on time needed for diagnosis and treatment. Costs were extrapolated over the patient’s total treatment phase. RESULTS: In total 406 MDR-TB patients and 197 other TB patients were included in the survey: 169 MDR-TB patients and 25 other TB patients in Ethiopia; 143 MDR-TB patients and 118 TB patients in Indonesia; and 94 MDR-TB patients and 54 other TB patients in Kazakhstan. Total costs for diagnosis and current treatment episode for TB patients were estimated to be USD 260 in Ethiopia, USD 169 in Indonesia, and USD 929 in Kazakhstan, compared to USD 1838, USD 2342, and USD 3125 for MDR-TB patients, respectively. These costs represented 0.82–4.6 months of pre-treatment household income for TB patients and 9.3–24.9 months for MDR-TB patients. Importantly, 38–92 % reported income loss and 26–76 % of TB patients lost their jobs due to (MDR) TB illness, further aggravating the financial burden. CONCLUSIONS: The financial burden of MDR-TB is alarming, although all TB patients experienced substantial socioeconomic impact of the disease. If the patient is the breadwinner of the family, the combination of lost income and extra costs is generally catastrophic. Therefore, it should be a priority of the government to relieve the financial burden based on the cost mitigation options identified. BioMed Central 2016-09-05 /pmc/articles/PMC5011357/ /pubmed/27595779 http://dx.doi.org/10.1186/s12879-016-1802-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article van den Hof, Susan Collins, David Hafidz, Firdaus Beyene, Demissew Tursynbayeva, Aigul Tiemersma, Edine The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan |
title | The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan |
title_full | The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan |
title_fullStr | The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan |
title_full_unstemmed | The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan |
title_short | The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan |
title_sort | socioeconomic impact of multidrug resistant tuberculosis on patients: results from ethiopia, indonesia and kazakhstan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011357/ https://www.ncbi.nlm.nih.gov/pubmed/27595779 http://dx.doi.org/10.1186/s12879-016-1802-x |
work_keys_str_mv | AT vandenhofsusan thesocioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT collinsdavid thesocioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT hafidzfirdaus thesocioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT beyenedemissew thesocioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT tursynbayevaaigul thesocioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT tiemersmaedine thesocioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT vandenhofsusan socioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT collinsdavid socioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT hafidzfirdaus socioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT beyenedemissew socioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT tursynbayevaaigul socioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan AT tiemersmaedine socioeconomicimpactofmultidrugresistanttuberculosisonpatientsresultsfromethiopiaindonesiaandkazakhstan |